文献速递炎症性肠病

溃疡性结肠炎主动家庭粪便钙卫蛋白监测:前瞻性随机对照试验结果

Proactive Fecal Calprotectin Home Monitoring in Ulcerative Colitis: Results of a Prospective Randomized Controlled Trial.
PubMed 文献 · Gastroenterology · 2026-06-23

这项前瞻性多中心随机对照试验纳入716例改良部分Mayo评分≤2且无直肠出血的溃疡性结肠炎缓解期成人,比较标准治疗与每2个月家庭粪便钙卫蛋白监测共18个月或至症状复发。结果显示两组症状复发率均为32%,复发风险无差异(HR 1.05,95%CI 0.79-1.40),主动监测未预防症状复发。

要点

  • 缓解期UC患者每2个月家庭FC监测未降低症状复发风险(HR 1.05,95%CI 0.79-1.40)。
  • 两组症状复发率均为32%,至复发中位时间未达到。
  • 确认FC升高后按医生 discretion 调整治疗者复发频率较低(49% vs 55%),但复发风险无差异。

核心结论

  • 主动家庭FC监测若无方案化升级治疗,不能预防UC症状复发。

研究设计与样本

  • 前瞻性多中心随机对照试验,纳入改良部分Mayo评分≤2且无直肠出血的UC缓解期成人,随机分为标准治疗组或每2个月FC监测组,持续18个月或至症状复发。
  • 共入组716例,分析对照组308例、干预组303例;平均年龄42岁,47%为男性,45%使用进阶治疗。

主要发现

  • 两组症状复发率均为32%,至复发中位时间未达到。
  • 总体症状复发风险无差异(HR 1.05;95%CI 0.79-1.40),按疾病范围或进阶治疗使用分层亦无差异。
  • 确认FC升高后调整治疗的88例中复发频率较低(49% vs 55%),但复发风险无差异。
  • 次要终点包括医疗资源使用、药物使用和生活质量均无差异。

关键数值与推荐

  • FC≥250 μg/g时2周内行确认性FC检测,治疗调整由医生决定。

临床怎么用

  • 不应仅依赖主动家庭FC监测而缺乏方案化升级策略来预防UC症状复发。
  • FC监测发现升高后早期干预的获益尚需进一步研究确定。

局限性

  • 治疗调整由医生决定而非方案化,可能影响干预效果评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Elevated fecal calprotectin (FC), a biomarker of intestinal inflammation, can be detected 3 months before symptomatic flare in patients with ulcerative colitis (UC). We hypothesized that proactive home-based FC monitoring would prevent symptomatic flares in patients with UC in remission. METHODS: This prospective, multicenter clinical trial randomized adults with a modified partial Mayo score ≤2 and no rectal bleeding to standard care or FC testing every 2 months for 18 months or until symptomatic flare. Confirmatory FC testing was performed within 2 weeks for FC ≥250 μg/g; change in therapy was at physician discretion. Primary end point was time to symptomatic flare. Secondary end points included health care use, medication use, and quality of life. RESULTS: The trial enrolled 716 patients; 308 in the control arm and 303 in the intervention arm were analyzed. Mean age was 42 years, and 47% were men. Distribution of disease extent was similar in both arms, and 45% were on advanced therapy. Symptomatic flare occurred in 32% in both arms; median time to flare was not reached. There was no difference in risk for symptomatic flare overall (hazard ratio, 1.05; 95% confidence interval, 0.79-1.40), by disease extent, or advanced therapy use. Flare frequency was lower among the 88 who changed therapy after confirmatory elevated FC (49% vs 55%), but flare risk was not different. There were no differences in secondary end points. CONCLUSIONS: Our results suggest that proactive home-based FC monitoring without protocolized escalation does not prevent symptomatic flares. Additional studies are needed to define the optimal use of FC monitoring and the benefit of early intervention. CLINICALTRIALS: gov number: NCT03549988.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Rosenfeld G, Narula N, Leung Y, et al. Proactive Fecal Calprotectin Home Monitoring in Ulcerative Colitis: Results of a Prospective Randomized Controlled Trial. Gastroenterology. 2026. PMID: 42336164. doi:10.1053/j.gastro.2026.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。